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(these data will be reported in another manuscript that is to be submitted within a month).
b.
express these truncated forms of EGFR in either cells harboring endogenous SGLT1 such as prostate cancer PC3MM2 and DU145 cells or these cells overexpressed with exogenous SGLT1 and perform immuno-co-precipitation to determine the interacting domains.
We have found that the major SGLT1 interacting domain of EGFR is its autophosphorylation domain, 978-1120 amino acids. These data are shown in figure 2 , and reported in Publication Ref. #1.
Figure 2. The autophosphorylation domain of EGFR is required for its interaction with SGLT1.
A, Schematic diagram of constructs of human EGFR used in this study: WT, wild type EGFR; KD, kinase dead EGFR (R817M); ∆TM, transmembrane domain deletion (645-670aa); ∆Extra, extracellular domain deletion (1-644aa); ∆Intra, intracellular domain deletion (671-1210aa); ∆TK, tyrosine kinase domain deletion (670-977aa); ∆Autophos, autophosphoralization domain deletion (978-1210aa). B, Deletion of the entire intracellular domain or the autophosphorylation domain of EGFR significantly reduced its interaction with SGLT1. C, By increasing the expression level of the ∆Intra-EGFR, the ∆Intra-EGFR was coprecipitated with SGLT1. Immunoprecipitation coupled Western blot analysis of interactions between mutated EGFRs and SGLT1. IP, immunoprecipitation. IB, Immunoblot. Input, expression levels of indicated exogenous proteins in HEK293 whole cell lysates used for the IP. EGFR bands are indicated by arrowheads. Non-specific bands (NS) are indicated by arrows.
c.
Co-express full length SGLT1 with truncated forms of EGFR in HEK293 cells and determine the stability of SGLT1 expression in these cells.
We have found that expression of the SGLT1 interacting domain deleted EGFR destabilizes SGLT1 protein, which is shown in figure 3 . These data have been reported in Publication Ref. #1 . 
ACCOMPLISHMENTS
We have successfully accomplished this task. We found that the C-terminal autophosphorylation domain of EGFR is the major SGLT1 interacting domain. We have reported this finding in a manuscript that was accepted for publication two weeks ago (attachment #1)(Ref. 1).
2.
To test whether cell survival is compromised upon disruption of the interaction between EGFR and SGLT1 by interfering peptides.
a.
design interfering peptides that have the similar sequence as the SGLT1-interacting domains of EGFR. b.
create vectors expressing these interfering peptides identical to the interacting domains and chemically synthesize these peptides.
c.
treat prostate cancer cells, PC3-MM2 and DU145, with the interfering peptides, and determine the survivability of the treated cells as compared with control cells.
ACCOMPLISHMENTS
We have tested 7 peptide candidates, and one of the 7 peptides showed effectiveness in down-regulating EGFR and SGLT1, and decreasing the survivability of PC3 cells (data shown below in Figure 3) . A provisional patent has been filled. Data will be published in another manuscript after filling a non-provisional patent. 
3.
To profile the expression of SGLT1 and EGFR in tissues of well characterized prostate cancer tissues.
We have accomplished this task. We found that SGLT1 and EGFR colocalized in all EGFR positive prostate cancer tissues tested (n=41), which are shown in Figure 4 and 5. These data were included in the manuscript (attachment #1, #2) (1, 2). 
CONCLUSION:
The tyrosine kinase activity of EGFR has served as the primary target for EGFR based cancer therapies. At the clinic, inhibition of the tyrosine kinase of EGFR by small molecules has produced responding rates ranging between 10-20% across a variety of human malignancies, however, with no exception of development of drug resistance within few months after treatment. Mechanisms whereby cancers primarily resist or acquire resistance to EGFR tyrosine kinase inhibitor (TKi) have been largely attributed to the gain of functions of EGFR and/or other pro-survival signalings subsequent to inhibition of EGFR tyrosine kinase. A critical question remains to be answered is that "why there are patients bearing EGFR overexpressing cancers do not response to EGFR TKi?" Prostate cancer (PC) is one representative type cancer wherein EGFR expression increases along with disease progression, but, in general, it is highly resistant to EGFR TKi treatment.
Our study has found that EGFR in cancer cells can exist as either a tyrosine kinase modulator responsive status or an irresponsive status. SGLT1 is a protein involved in EGFR's functions that are irresponsive to EGFR tyrosine kinase inhibitors, EGFR and SGLT1 colocalized in prostate cancer cells, and disruption the EGFR-SGLT1 interaction decreased the survivability of prostate cancer cells and, targeting EGFR-SGLT1 interaction shall be a novel therapeutic approach for prostate cancer treatment.
PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:
a. Publications (1) Lay Press: None (2) Peer-Reviewed Scientific Journals:
1. Xu S. Evidence indicates that EGFR has tyrosine kinase 7 independent functions. While EGFR knockout ani-8 mals die soon after birth [11] , mice with severely 9 compromised EGFR tyrosine kinase activity are 10 viable and display only some epithelial defects 11 [12] . Both a wild-type and a kinase-dead EGFR 12 enhance the survival of EGFR-negative 32D hemato-13 poietic cells [13] . Previously, we found that, indepen-14 dent of EGFR tyrosine kinase activity, EGFR 15 participates in the maintenance of basal intracellular 16 glucose level of cancer cells by interacting with 17 and stabilizing the sodium/glucose co-transporter 18 1 (SGLT1) [14] .
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SGLT1 is an active glucose transporter that relies on 20 extracellular sodium concentration to transport glucose 21 into cells independent of glucose concentration [15] . 22 SGLT1 plays a critical role in glucose absorption and 23 retention in the body [16] . One of the hallmarks of 24 cancer is that cancer cells exhibit altered energy 25 metabolism, that is, cancer cells consume higher 26 amounts of nutrients and energy substrates than their 27 normal counterparts [17] . This enhanced energy con-28 sumption demands a high rate of nutrient uptake, 29 which is achieved by overexpression of plasma mem-30 brane transporters [18] . SGLT1 is overexpressed in 31 various types of cancers including ovarian carcinoma 32 [19] , oral squamous cell carcinoma [20] , colorectal 33 cancer [21] , pancreatic cancer [22] , and prostate 34 cancer [23] . Prostate cancers at late stages express 35 elevated levels of EGFR [5] [6] [7] and uptake a high 36 amount of glucose [24, 25] . Whether the relationship 37 between EGFR and SGLT1 can be manipulated for 38 therapy of prostate cancer remains unknown. 39 In this study, we characterized the critical domain 40 of EGFR that is required for its sufficient interaction 41 with SGLT1. We also determined the effects of activa-42 tion/inactivation of EGFR tyrosine kinase activity on 43 EGFR-SGLT1 interaction, measured the expression of 44 was from ATCC. The plasmid expressing flag tagged human SGLT1 and the rabbit anti-human-SGLT1 polyclonal antibodies for immunohistochemical analysis (SGLT1-IHC), immunoprecipitation, and Western blotting analysis (SGLT1-WB) were described previously [23] .
Plasmid Constructions
Human wild-type EGFR was cloned into a pcDNA3.1 vector (Clontech, CA), which was used as a parental vector to generate all the other EGFR constructs. The pRK5 expression plasmid (Clontech) with a c-terminal HA tags was used for constructions of all the HA tagged EGFRs. The full-length human EGFR was amplified with a forward primer EGFR-F (ATTCTCGAGCGGGGAGCA GCGATG) and a reverse primer EGFR-R (CCTAAGCTTTGCTCCAA-TAAATTCACTG). DNA fragments were digested by Xho I and Hind III and cloned into the corresponding sites of the pRK5 vector. Primers for cloning the EGFR with extracellular domain deletion (DExtra, 1-644aa) are DExtra-F: ATTCTCGAGATGTCC ATCGCCACTG-GGATG and DExtra-R: CCTAAGCTTTGCTCCAA-TAAATTCACTGC; primers for intracellular deletion (DIntro, 671-1210aa) are DIntra-F: TATCTCGAGATG-CGACCCTCCGGGACGGC and DIntra-R: CCTAAG-CTTCC TTCGCATGAAGAGGCC; primers for autophosphorylation domain deletion (DAutophos, 978-1210aa) are DAutophospho-F: ATTCTCGAGATGTC-CATCGCCACTGGGATG and DAutophospho-R: CC-TAAGCTT GTAGCGCTGGGGGTCTCGG; primers for intracellular domain deletion (645-1210aa) are DIntra-F: TATCTCGAGATGCGACCCTCCGGGACGGC and DIntra-R:
CCTAAGCTTCCTTCGCATGAAGAGGC. The kinase dead mutant of EGFR (KD-EGFR, R817M), transmembrane domain deletion (DTM, 645-670aa), tyrosine kinase domain deletion (DTK, 670-977aa) plasmids were constructed from pRK5-WT-EGFR-HA by site-directed mutagenesis using the QuikChange 
Cell Growth Assay
Cell growth was determined by 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 96-well plates according to the protocol provided by the manufacture. Briefly, 5,000 cells suspended in 100 ml medium were seeded in each well of a 96-well plate. On the second day, medium was replaced by medium containing Phl o -zidin Q2 (50 mM) with/without EGFR inhibitors (Gefitinib: 20 mM; Erlotinib: 20 mM). After 24 or 48 hr incubation with drugs, 10 ml MTT reagents was added to each well and incubated for 4 hr. After removal of the medium, the formazan precipitates in cells were dissolved in 100 ml DMSO. Absorbance was measured by a MultiSkan plate reader (Thermo Fisher Scientific, NC) at 570 nm. Triplicates of samples in each group were used.
Statistical Analysis
The Student's t-test was used to assess the difference in growth of cells treated with EGFR inhibitors in the presence/absence of SGLT1 inhibitor. P values less than 0.05 were defined as statistical significance. determine the region in EGFR protein that is critically required for its interaction with SGLT1, we created flag-tagged SGLT1 [23] and HA-tagged EGFRs with a variety of mutations. These mutated EGFRs include a kinase dead form (R817M) (KD-EGFR), an extracellular domain deleted form (DExtra), a transmembrane domain deleted form (DTM), an intracellular domain deleted form (DIntra), a tyrosine kinase domain deleted form (DTK), and an autophosphorylation domain deleted form (DAutoPhos) (Fig. 1A) . We transiently co-transfected an 49 Fig. 1 . The autophosphorylation domain of EGFR is required for its interaction with SGLT1. A: Schematic diagram of constructs of human EGFR used in this study: W T, wild-type EGFR; KD, kinase dead EGFR (R817M); DTM, transmembrane domain deletion (645 ^ 670aa); DExtra, 50 extracellular domain deletion (1^ 644aa); DIntra, intracellular domain deletion (671^1210aa); DTK, tyrosine kinase domain deletion (670 ^ 51 977aa); DAutophos, autophosphorylation domain deletion (978 ^1210aa). B: Deletion of the entire intracellular domain or the autophosphor-52 ylation domain of EGFR significantly reduced its interaction with SGLT1. C : By increasing the expression level of the DIntra-EGFR, the 53 DIntra-EGFR was co-precipitated with SGLT1. Immunoprecipitation coupled Western blot analysis of interactions between mutated EGFRs 54 and SGLT1. IP, immunoprecipitation; IB, immunoblot. Input, expression levels of indicated exogenous proteins in HEK293 whole cell lysates 55 used for the IP.EGFR bands are indicated by arrowheads.Nonspecific bands (NS) are indicated by arrows. conditions, the DIntra-EGFR was not co-precipitated 42 with SGLT1, which might be due to the expression 43 level of the DIntra-EGFR was much lower than the 44 other forms (Fig. 1B) . To increase the expression 45 level of the DIntra-EGFR, we increased the amount 46 of plasmid cDNA of DIntra-EGFR by threefold for 47 co-transfection. We found that the DIntra-EGFR was 48 co-precipitated with SGLT1, however to a much less 49 extent as compared with the WT-EGFR and the KD-50 EGFR that were expressed at a comparable level 51 (Fig. 1C ). These data indicate that the Autophos 52 domain of EGFR is the major SGLT1 interacting 53 domain, however the extracellular domain contain-54
ing the transmembrane domain of EGFR, the DIntra-55 EGFR, can weakly interact with SGLT1.
The Autophosphorylation Domain of EGFR Is Required to Prevent Proteasome -Mediated SGLT1 Degradation
To determine whether the SGLT1-interacting domain of EGFR is required to sustain the stability of SGLT1, we measured the expression level of SGLT1 cotransfected with the WT-EGFR, the KD-EGFR and the DAutoPhos-EGFR into HEK293 cells. As shown in Figures Figure 2A and Figure 3B , the level of SGLT1 in the WT-EGFR and the KD-EGFR transfected cells is much higher than that in the control vector or DAutoPhos-EGFR transfected cells, suggesting the autophosphorylation domain of EGFR is needed to maintain the expression level of SGLT1. In addition, the level of SGLT1 in the DAutoPhos-EGFR transfected cells was also significantly lower than that of the control cells, suggesting that loss of interaction with EGFR may promote down-regulation of SGLT1. To determine whether proteasome is involved in loss of interaction with EGFR induced down-regulation of SGLT1, we treated SGLT1 and DAutoPhos-EGFR co- Knowing that the tyrosine kinase activity of EGFR 44 is not required for its interaction with SGLT1 ( Fig. 1) , 45 we sought to determine the effects of EGFR ligand and 46 its tyrosine kinase inhibitors on its interaction with 47 SGLT1. We treated WT-EGFR and SGLT1 co-trans-48 fected HEK293 cells with either EGF or an EGFR 49 tyrosine kinase inhibitor, AEE788. We then immuno-50 precipitated SGLT1 and measured the levels of EGFR 51 that were co-immunoprecipitated with SGLT1. As 52 shown in Figure 3A , neither EGF nor AEE788 affected 53 EGFR-SGLT1 interaction and the EGFR co-precipitat-54 ed with SGLT1 was not phosphorylated. To further 55 determine the effects of EGF and AEE788 on endogenous EGFR-SGLT1 interaction and the phosphorylation status of endogenous EGFR that interacts with SGLT1, we immunoprecipitated the endogenous SGLT1 of PC3 cells treated with EGF or AEE788 and measured the phosphorylation status of the EGFR coprecipitated with SGLT1. We found that neither EGF nor AEE788 affected the EGFR-SGLT1 interaction and the endogenous SGLT1 interacting EGFR was not phosphorylated either (Fig. 3B ). These results suggest that the EGFR-SGLT1 interaction is irresponsive to modulators of EGFR tyrosine kinase activity.
EGFR and SGLT1 Co -Localize in Prostate Cancer
Tissues and Inhibition of SGLT1 by a SGLT1 Inhibitor Sensitized Prostate Cancer Cells to EGFR Inhibitors
To determine the clinical relevance of EGFR-SGLT1 interaction, we performed immunofluorescent costaining of EGFR and SGLT1 on a tissue microarray of prostate cancers (n ¼ 44). In all the EGFR-positive cancer samples (n ¼ 41), we found SGLT1 co-localized with EGFR in cancer cells but not the stromal cells
The Prostate 1 (Fig. 4A ). These data suggest that EGFR-SGLT1 2 interaction may contribute to the pathogenesis of 3 prostate cancer. 4 It is known that an increase in glucose levels can 5 activate EGFR [26] , that SGLT1 is overexpressed in 6 prostate cancer tissues [23] , and that prostate cancer is 7 resistant to EGFR inhibitors [9, 10] . We speculated that 8 SGLT1 and EGFR may synergistically promote pros -9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 tate cancer growth. To test whether inhibition of SGLT1 can sensitize prostate cancer cells to EGFR inhibitors, we treated prostate cancer cell lines, PC3 and LNCaP (both positive for EGFR and SGLT1) (Fig. 4B) , with EGFR tyrosine kinase inhibitors, Gefitnib and Erlotinib, in the presence/absence of a SGLT1 inhibitor, Phlorizin [27] , and determined the growth inhibitory effects of the treatments. It was found that Phlorizin was additive to the growth inhibitory effects 2 of Gefitnib and Erlotinib (Fig. 4C,D) .
Previously, using EGFR's extracellular domain 7 and intracellular domain that does not contain the 8 TM domain of EGFR, we reported that SGLT1 9 interacted stronger with the extracellular domain of 10 EGFR than the intracellular domain of EGFR [14] . To 11 further characterize the EGFR-SGLT1 interaction at 12 the plasma membrane, we included the TM domain 13 in to the constructs of truncated EGFRs. We found 14 that the TM containing intracellular domain of 15 EGFR, especially the autophosphorylation domain, 16 interacted with SGLT1 much stronger than the 17 extracellular domain of EGFR. The discrepancy 18 between current data and the data shown in the 19 previous report [14] is likely due to the lack of TM 20 domain in the intracellular domain construct of 21 EGFR used in the previous study. The findings that 22 the autophosphorylation domain of EGFR interacts 23 with SGLT1 and this interaction is independent of 24 activation/inactivation of EGFR (Figs. 1-3 The co-localization of EGFR with SGLT1 in prostate 49 cancer tissues strongly indicates that the EGFR-SGLT1 50 interaction is relevant to cancer metabolism. In the 51 clinic, EGFR tyrosine kinase inhibitors did not produce 52 therapeutic effects for prostate cancer [9, 10] . Consider-53 ing the fact that EGFR expression correlates with 54 disease progression of prostate cancer and the clinical 55 unresponsiveness of prostate cancers to EGFR tyrosine kinase inhibitors, we propose that EGFR may contribute to the disease progression of prostate cancer independent of its tyrosine kinase activity. Previously, we have found that prostate cancer tissues have increased expression of SGLT1 [23] , loss of EGFR protein but not its tyrosine kinase activity sensitized prostate cancer cells to chemotherapeutic agent [29] , and loss of EGFR-induced autophagic cell death was mediated by down-regulation of SGLT1 protein [14] . These data suggest that EGFR can promote prostate cancer progression via stabilizing SGLT1 to sustain the high demand of glucose by late stage cancer cells. This possibility is supported by our data that treatment of prostate cancer cells with a SGLT1 inhibitor sensitized cancer cells to EGFR inhibitors (Fig. 5 Q3 ), as well as data demonstrating that overexpression of SGLT1 protected renal epithelial cells [30] and intestinal epithelial cells [31] from apoptosis.
The deletion of the SGLT1 interacting domain in EGFR promoted the down-regulation of SGTL1 via the proteasome machinery (Fig. 2) , suggesting that disruption of EGFR-SGLT1 interaction in EGFR-positive cancer cells may lead to down-regulation of SGLT1. Given that knocking down SGLT1 by shRNA resulted in autophagic cell death of prostate cancer cells [14] , it is suggested that the EGFR-SGLT1 interaction might be a novel target to improve EGFR-based therapy for prostate cancer. 
Introduction
Influx of glucose into cells is carried out by two main classes of glucose transporters, the facilitative glucose transporters (GLUTs) and the active sodium/glucose co-transporters (SGLTs) [1] . GLUTs mediate a concentration-dependent and energy-independent bidirectional process of glucose transport. In contrast, SGLTs mediate an active Na + gradient-dependent glucose uptake regardless of the extracellular glucose concentration [2, 3] . The SGLT family consists of 3 members, SGLT1, SGLT2, and SGLT3 [1] ; the last may function as a glucose sensor rather than a transporter [4] .
Increased glucose uptake and GLUT expression are associated with pathological conditions, such as hypoxia, inflammation, and neoplasia. Hypoxia induces GLUT1 expression in neurons [5, 6] and chondrocytes [6] , and inflammation up-regulates GLUT1 in macrophages [7] and vascular endothelial cells [8] . GLUT1 is often induced in many cancers, including those of the breast, cervix, esophagus, lung, and liver [9] . Increased expressions of SGLT1 have been found in oral cancer [10] , colorectal cancer [11] , pancreatic cancer [12] , and ovarian cancer [13] .
Normal prostatic epithelium is not active in glucose metabolism [14] . However, glucose uptake has often been observed with high-grade prostate cancer (PCa) [15] hinting at an association between altered glucose metabolism and the pathogenesis of PCa. Yet several studies have found significantly decreased levels of GLUT expression in PCa [16, 17] . The glucose transporter or transporters that are involved in the increased glucose uptake observed in PCa remain to be investigated.
To explore the possibility of a role for SGLT in pathogenesis of prostate diseases, we produced and characterized two rabbit polyclonal antibodies against human SGLT1 to examine its expression levels in human prostate tissues including normal, benign prostate hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and PCa.
Materials and Methods

Antibody production and purification
Two peptides, CIETQVPEKKKGIFRR and CLRNSKEERIDLDAE, corresponding to amino acids 588-604 and 563-576 of human SGLT1 were used to raise rabbit polyclonal antibodies suitable for immunohistochemical analysis (SGLT1-IHC) and Western blotting (SGLT1-WB) respectively.
HiTrap affinity columns (General Electric, Uppsala, Sweden) were used to purify the SGLT1 antibodies from SGLT1 antiserum. To purify the antibody, the columns were coupled with the antigenic peptide at a concentration of 1 mg/mL in coupling buffer (0.2 M NaHCO 3 , 0.5 M NaCl, pH=8.3) for 30 minutes at room temperature. The column was then exposed to buffer A (0.5 M ethanolamine, 0.5 M NaCl, pH=8.3) and buffer B (0.1 M acetate, 0.5 M NaCl, pH=4) 3 times. Five hundred microliters of the pre-immune serum and 500 µL of the antiserum were diluted in binding buffer (0.2 M NaH 2 PO 4 , pH=7.0) and passed through the column. The bound antibodies were eluted with 3 mL of elution buffer (1 M glycine-HCl, pH=2.7). The elutant was immediately neutralized with neutralizing buffer (1 M Tris-HCl, pH=9.0), and 0.02% Na 3 N was added to the purified antibody for long-term storage.
Cell culture
PC3, PC3-MM2, LNCaP, HCT116, and HEK293T were from our laboratory cell stocks. All types of cells were cultured in Dulbecco's modified Eagle's medium) (Invitrogen, Carlsbad, CA) and supplemented with 5.5 mM glucose, 10% fetal bovine serum, and 1% penicillin/streptomycin. Cells were cultured at 37°C with 5% CO 2 .
Plasmid construction
Human SGLT1 cDNA was amplified from a cDNA library using a pair of primers, GCTGCCACCATGGACAGTAG and CAG-CAAAAGGTAGGACTCAGG, corresponding to the 5′ and 3′ UTR of SGLT1. A second round of polymerase chain reaction was performed using a pair of nested primers, TGAGTCGACGGCAAAATATGCAT-GGCAAAAGACAGCCACGGTCACC and ATAGAATTCATGGA-CAGTAGCACCTGGAGCCCCAAGACCA. The polymerase chain reaction product of SGLT1 was cloned into a PXF2F expression vector between the SalI and EcoRI sites, which produced a SGLT1 cDNA with a FLAG tag at both the N-terminus and the C-terminus. The construct was confirmed by sequencing. The tagging at both ends allows the protein to be expressed at a stable level in the absence of epidermal growth factor receptor (EGFR) and was used as a positive control for antibody characterization.
The U6 promoter-driven small interfering (shRNA) vector with green fluorescent protein (GFP) expression (pRNAT-U6.1/Neo; GenScript)wasusedtoexpressshRNAagainstSGLT1.Thetargetsequence for SGLT1 shRNA was TCTTCCGCATCCAGGTCAAT. The negative control shRNA sequence was GAACAATGTTGACCAGGTGA.
shRNA knockdown, RT-PCR and western blotting
Whole-cell lysates of intact cells were transfected with vectors expressing FLAG-tagged SGLT1 in combination with vectors expressing SGLT shRNA or its corresponding scrambled control. At the time of transfection, cells were cultured in their respective media without the supplemented 1% penicillin/streptomycin. Six hours post-transfection, the media were replaced with normally formulated media. At 48 hours after transfection, one set of cells were used for RNA isolation and RT-PCR determination of SGLT1 mRNA (primers are: 5′-TGGCAGGCCGAAGTA-TGGTGT-3′ and 5′-ATGAATATGGCCCCCGAGAAGA-3′) and beta actin as an internal control (5′-ATCTGGCACCACACCTTCTACAATG-3′ and 5′-CGTCATACTC-CTGCTTGCTG-3′). The RT-PCR reaction program was set to 50°C for 1 hr and 94°C for 5 min, followed by 30 cycles of 94°C for 40 s, 56°C for 40 s, and 72°C for 50 s with an extension at 72°C for 10 min. The PCR products were analyzed with a 1% agarose gel stained with ethidium bromide and visualized under ultraviolet light. Another set of cells were lysed for 30 minutes on ice in RIPA buffer (Sigma Aldrich, St. Louis, MO) supplemented with protease and phosphatase inhibitors for Western Blot and immunoprecipitation assays. The concentrations of the protein samples were measured using a Qubit flourometer (Invitrogen), and equal amounts of protein samples were loaded onto a 10% SDS-PAGE gel and transferred to a polyvinylidine fluoride membrane. Membranes were incubated in 5% milk to block the non-specific binding sites for 30 minutes and then in optimized concentrations of SGLT1-WB or primary anti-FLAG antibody (Santa Cruz Biotechnology, Santa Cruz, California) at 4°C overnight. After being washed with 3x phosphate-buffered saline (PBS), membranes were incubated with horseradish peroxidaseconjugated secondary antibodies (Santa Cruz Biotechnology) at 1:3000 dilutions for 1 hour at room temperature. Luminescent signals were detected using an enhanced luminescence kit (Pierce ThermoScientific, Rockford, IL) and exposed to X-ray film (VWR, Bridgeport, NJ).
Immunoprecipitatioin
HEK 293 cells were transfected with double flagged SGLT1. After 24 hours of post transfection cells were washed in 1X phosphate buffered solution and lysed with RIPA buffer (50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate), supplemented with ptotease inhibitors cock tail, for 6 hours at 4°C on a shaker. The cell lysates were then centrifuged for 2 minutes at 12000 rpm and 500 µgs of supernatants were incubated with 25 µl of sepharose protein A/G beads (Santa Crusz Biotechnology, Santa Cruz, CA, USA) conjugated with 500 ng anti-flag antibody (Sigma) for overnight. Samples were then centrifuged and washed with RIPA buffer three times before boiled in Laemmle buffer (Biorad, Hercules, CA, USA) and subjected to Western blot analysis using the SGLT1-WB antibody.
shRNA knockdown and immunocytochemical analysis
Vectors expressing SGLT shRNA or its corresponding scrambled control were transiently transfected into HCT116 cells cultured on collagen-coated glass coverslips using Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen). At the time of transfection, cells were cultured in their respective media without the supplemented 1% penicillin/streptomycin. Six hours post-transfection, the media were replaced with normally formulated media. At 30 hours posttransfection, cells were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) in PBS.
Slides were blocked by incubating cells in normal goat serum for 1 hour followed by primary antibody against SGLT1 (1:200 in PBS) overnight at 4°C. After being washed, cells were exposed to Alexa Fluor 594 secondary antibody (1:200; Invitrogen) for 1 hour at room temperature. After three washes with PBS, coverslips were mounted on microscopic slides using 10 µl of VECTASHIELD mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA). Fluorescence images were captured and analyzed with a fluorescent Olympus microscope.
Tissue preparation
Paraffin-embedded tissue microarrays containing normal human tissues and human prostate tissues, BPH tissues, PIN tissues, and PCa tissues were purchased from Lifespan Biosciences (Seattle, WA). An additional five BPH tissue samples were obtained from the Methodist Hospital Research Institute's Department of Urology (Houston, TX) tissue bank under the approval of its institutional review board.
IHC analysis
Immunoperoxidase staining: For immunoperoxidase staining with diaminobenzidine labeling, tissue sections were deparaffinized in xylene and rehydrated in a graded series of alcohol and PBS. Antigen retrieval was performed using heated citrate buffer. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol. Samples were incubated in a blocking solution (5% donkey serum in PBS) for 1 hour at room temperature and then overnight at 4°C with the primary antibody against SGLT1 diluted in the blocking solution (1:200). After three washes in PBS, samples were incubated with a biotinylated goat anti-rabbit secondary antibody (1:500) for 1 hour at room temperature and then washed thoroughly. An ABC staining kit was used for chromogenesis. Slides were then briefly counterstained with hematoxylin and mounted.
Immunofluorescent co-staining: For immunofluorescent costaining of SGLT1 and tenascin, tissue slides were co-incubated with the rabbit polyclonal antibody against SGLT1 (1:200 dilution, or with 1 mg/mL blocking peptides for the control) and a monoclonal antitenascin antibody (1:200) in PBS containing 10% donkey serum. After being washed three times with PBS, tissues were incubated with Alexa Fluor 488-conjugated donkey anti-rabbit immunoglobulin G, Alexa Flour 594-conjugated donkey anti-mouse immunoglobulin G, or both (Invitrogen) in PBS containing 10% donkey serum for 30 minutes at room temperature. The stained samples were then washed three times (5 minutes per wash) with PBS, also at room temperature. Fluorescence images were captured and analyzed with a confocal microscope (Olympus).
Results
75
Characterization of rabbit antibodies against human SGLT1
SGLT1-WB:
The specificity of SGLT1-WB was characterized by the following experiments. First, we transiently transfected FLAGtagged SGLT1 plasmids with either SGLT1 shRNA or control shRNA into HEK293T cells and determined the levels of FLAG-tagged SGLT1 of these cells by Western blotting using a primary antibody against IB-SGLT1-WB Actin Actin FLAG. The flagged SGLT1 produced four major bands of >250, 150, 80, and 55 kDa, which were all substantially reduced only by the SGLT1 shRNA in a dose-dependent manner ( Figure 1A ). The >250 kDa and 150 kDa bands might be aggregates of overexpressed SGLT1. Because the exogenous SGLT1 was flagged at both the N-and C-termini, the expected molecular weight was 80 kDa. The 55 kDa band is likely degraded SGLT1. Using the same set of cell lysates, we detected the expression of SGLT1 in these cells using the SGLT1-WB primary antibody. The results were similar, will all four bands detected by Normal BPH SGLT1-WB reduced by SGLT1 shRNA in a dose-dependent manner ( Figure 1B ). To further determine the specificity of the SGLT1-WB A antibody, we performed an assay of immunoprecipitation coupled with Western blot (IP-WB) using the anti-flag antibody for IP and the SGLT1-WB for WB, and an irrelevant rabbit IgG as a negative control. As shown in Figure 1C , the immunoprecipitated flagged SGLT1 was detected by the SGLT1-WB antibody. We then determined the expression of endogenous SGLT1 in a panel of cell lines PC3, PC3-MM2, and LNCaP. SGLT1-WB detected a single band at the expected 75 kDa (endogenous SGLT1) in the PC3, PC3-MM2, and LNCaP lines B ( Figure 1D ). To determine the specificity of the endogenous SGLT1 signal, we transiently transfected SGLT1 shRNA and its control shRNA into PC3 cells and determined the expression levels of the endogenous SGLT1 using SGLT1-WB. The SGLT1 signal was reduced by the addition of SGLT1 shRNA ( Figure 1E ). Taken together, these data suggest that SGLT1-WB is suitable for Western blot analysis.
SGLT1-IHC:
To characterize the SGLT1-IHC antibody, we conducted two types of control experiments. First, we tested the C specificity of this antibody by using immunocytochemical analysis on cells treated with control shRNA or SGLT1 shRNA. Because colon cancers express SGLT1 (11) cells as a positive control. The expression of SGLT1 in HCT116 cells treated with control shRNA or SGLT1 shRNA was first confirmed by Western blotting using the SGLT1-WB antibody (Figure 2A) and RT-PCR analysis of the SGLT1 mRNA ( Figure 2B ). Then we performed immunocytochemical staining using SGLT1-IHC with HCT116 cells. The shRNA expression vector expresses green fluorescent protein (GFP) under an autonomous CMV promoter-that is, cells that have taken up the shRNA vector are GFP-positive, which allows us to distinguish shRNA-transfected cells from non-transfected cells. We used Alexa Fluor 594-conjugated secondary antibody to label the SGLT1-IHC signal. The control shRNA transfected and nontransfected cells presented equal levels of SGLT1; however, the SGLT1 signal was significantly reduced in the SGLT1 shRNA-transfected cells compared with the control shRNA-transfected and non-transfected cells ( Figure 2C ). To further characterize SGLT1-IHC, we compared the immunohistochemical signals produced by SGLT1-IHC in the absence or presence of its blocking peptides in normal human intestine tissue, which is known to express SGLT1 [18] and a SGLT1 negative tissue, the brain [19] . SGLT1-IHC gave rise to clear positive signals in the epithelial cells of the small intestine, which were significantly reduced by its blocking peptides, and the brain tissue was completely negative ( Figure 2D ). Together, these results show that SGLT1-IHC is specific for endogenous SGLT1.
SGLT1 up-regulation in diseased human prostatic tissue:
Using SGLT1-IHC, we profiled the expression of SGLT1 in samples of normal prostate (n=3), BPH (n=53), PIN (n=9), and PCa (n=44). SGLT1 was weakly expressed in the luminal epithelial cells of normal tissue ( Figure 2D ). All the BPH tissues had a discontinuous layer of basal cells with high levels of SGLT1 expression as well as SGLT1-positive stromal cells (Figure 3 ). Even greater SGLT1 expression was consistently observed in the epithelial cells of PIN samples (Figure 4) . Cancer cells of all the prostate cancer samples were strongly positive for SGLT1 ( Figure 5) . Overall, the examples exhibited a pattern of membranous or cytoplasmic staining in cells of lower grade cancers and nuclear envelope staining in cells of high-grade cancers. SGLT1-positive stromal cells were also observed in PIN and PCa tissues but to a lesser extent than in the BPH samples. A semiquantitative summary of SGLT1 expression in these prostatic tissues is presented in Table 1 .
SGLT1-positive, tenascin-negative stromal cells in diseased human prostatic tissue:
Tissue stromal cells can be activated by pathological insults, which is often the case for diseased prostates [20, 21] . Because we observed that stromal cells of BPH tissues and some PCa tissues were positive for SGLT1, we performed immunofluorescent co-staining of SGLT1 with a reactive stromal cell marker, tenascin [21] , to determine whether the SGLT1-positive stromal cells were reactive stromal cells. To our surprise, the SGLT1-positive stromal cells were tenascin negative (Figure 6 ), suggesting they are not reactive stromal cells in BPH or PCa tissue.
Discussion
The normal human prostate gland produces, accumulates, and secrets high levels of citrate, which is predominantly derived from the oxidation of fatty acids [22] . Because the normal prostate is not active in glucose metabolism but relies on fatty acid metabolism, the role of glucose and its transporters in prostate biology has not been adequately investigated. However, emerging data suggest that both BPH and PCa are associated with altered glucose metabolism. Blood glucose levels positively correlate with prostate size in BPH [23] and the incidence of both BPH and PCa correlates with metabolic syndrome [24] of which glucose intolerance is one of the major abnormalities. In addition, high-grade PCa and PCa metastases exhibit increased glucose uptake [15, 25] . Moreover, PCa cells are sensitive to glucose starvation-induced autophagy [26] . The cumulative evidence strongly suggests that glucose metabolism is critically involved in the pathogenesis of prostate diseases, such as BPH and PCa.
Our study shows that the expression of SGLT1 is significantly increased in basal cells and stromal cells of BPH tissue compared with normal prostate tissue. The heterogeneous expression of SGLT1 in the basal cells and stromal cells of BPH is intriguing, which suggests that neither cell type is metabolically homogenous. These results strongly suggest a one-way glucose flux from the basal cells to the luminal epithelial cells in the normal prostate. The biological roles of SGLT1-positive basal cells and stromal cells in the pathogenesis of BPH demand further study.
The highly increased expression of SGLT1 in the epithelial cells of PIN and PCa cells relative to the cells of normal prostate and BPH tissues suggests that a high level of glucose is required during the pathogenesis of PCa. GLUT1 has been found to be expressed exclusively in luminal epithelial cells and in borders between the basal and luminal epithelial cells [17] and GLUT1 expression is decreased in PCa cells compared with non-cancer cells [16, 17] . This shift from GLUT1 to SGLT1 in epithelial cells indicates a higher demand for glucose during the pathogenesis of PCa.
The stroma of PCa tissues also contains regions with a variable positive reactive stromal cells [27] . Reactive stromal cells have been show to play critical roles in the pathogenesis of BPH and PCa [20, 28] . These data added another layer of complexity to our increasing understanding of the role of stromal cells in the development of PCa and BPH. The variability of SGLT1-positive stroma in PCa might [29] when tumor foci are small and scattered, because the FDG uptake by SGLT1-positive stromal cells may overshadow the uptake by cancer foci. The translocation of SGLT1 into the nuclear envelope of high-grade PCa that we observed is also intriguing and is reminiscent of proteins such as pyruvate kinase M2 [30] protein kinase C η [31] CXCR4 [32] annexin A1 [33] and EGFR [34] that reside in the nonnuclear compartments of normal cells and translocate to the nucleus of cancer cells, where they are involved in nuclear events critical for cancer cell proliferation and survival.
The overall expression pattern of SGLT1 in normal prostate, BPH, and PCa tissues is very similar to the expression pattern of EGFR, which is weakly expressed in the epithelial cells of normal prostate tissue, moderately expressed in the stromal cells in BPH, and significantly increased in cancer cells [35] [36] [37] [38] . These findings suggest that SGLT1 and EGFR expression might be regulated under a common mechanism, and they support our previous finding that EGFR interacts with or stabilizes SGLT1 in PCa cells [39] . Further investigation is needed to understand the association between EGFR and SGLT1 during the development of PCa. 
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INTRODUCTION
The epidermal growth factor receptor (EGFR) is over-active in most types of tumors of epithelial origin [1] . Since EGFR is a receptor tyrosine kinase and activation of EGFR most often results in cell proliferation and enhanced cell survival, blocking the tyrosine kinase activity of EGFR has been a strategy of cancer therapy. Analogues of ATP that can compete for binding of ATP to EGFR in either competitive or non-competitive manners have been developed, and some have already been used in the clinic [2] .
In prostate cancer, EGFR is elevated along with disease progression. In the normal prostate EGFR expression is low [3] . Compared to the tumor cells of the primary site, it was found that prostate cancer bone metastases express significantly higher level of EGFR [4] . Studies have shown that increased levels of EGFR immunoreactivity in hormone-independent human prostate cancer cell lines [5, 6] . More interestingly, EGFR expression increases as prostate cancer progresses from an androgen dependent to an androgen independent stage [7] . In tissues of patients with meta-static androgen-independent prostate cancer, EGFR over-expression was detected in most cancer cells [8, 9] . However, despite the positive correlation of the expression level of EGFR with disease progression, targeting EGFR kinase activity has not yet produced positive clinical outcomes for prostate cancer treatment [10] .
Evidence supporting a kinase independent prosurvival function of EGFR exists. For example, both the wild-type and kinase-dead EGFR showed a pro-survival role in EGFR negative 32D hematopoietic cells [11] ; knocking down EGFR with small interfering RNA (siRNA) resulted in cell death [12] [13] [14] , while most often EGFR tyrosine kinase inhibitors cause cell growth arrest rather than cell death [15] ; EGFR knockout animals die soon after birth [16] , but animals with severely compromised EGFR kinase activity are completely viable and display only epithelial defects [17] . We have recently found that EGFR, independent of its kinase activity, protects cancer cells from undergoing autophagy [18] .
Autophagy, a process of self-digestion providing cells with enough nutrients and energy substrates for survival [19] , plays multi-faceted roles in tumor formation, progression, and drug resistance. The autophagy pathway can act as a tumor suppressor, a tumor protector, an anticancer drug-sensitizer or a desensitizer, depending on tumor type, stage and the kind of anticancer stimulus. Autophagy is tumor suppressive since mice that are haplo-insufficient for beclin 1, an upstream regulator of the autophagy pathway, are tumor-prone [20] . Loss of at least one allele of beclin 1, a protein required for autophagy, is found in many types of cancer cells [21] . Autophagy is also tumor protective since it enhances the survival of tumor cells in a nutrient deprived and hypoxic environment [22] , which is a hallmark of solid tumors. Blocking the autophagy pathway sensitizes chronic myelogenous leukemia cells to an anticancer drug suberoylanilide hydroxamic acid (a histone deacetylase inhibitor) [23] , while induction of autophagy sensitizes glioblastoma cells to chemotherapeutic agents [24] .
To further explore the possibility of targeting EGFR for prostate cancer therapy, we investigated whether loss of EGFR-induced autophagy can affect the sensitivity of prostate cancer cells to the chemotherapeutic agent, adriamycin.
MATERIALS AND METHODS
Reagents
The human hormone refractory metastatic prostate cancer cell line PC-3MM2 selected from the parental PC3 line [25] was a gift from Dr. Isaiah Fidler (MD Anderson Cancer Center, Houston). Du145 prostate cancer cells were purchased from American Type of Cell Culture (Manassas, VA). Minimum essential medium (MEM) containing 5.5 mM glucose, fluorescent conjugated caspases 3/7 substrates was purchased from Invitrogen (San Diego, CA). Glucose was from Sigma-Aldrich (St. Louis, MO). Antibodies against EGFR and pEGFR were from Cell Signaling (Danvers, MA). Horse radish peroxidase conjugated secondary antibodies against mouse or rabbit and AG1478 were from Santa Cruz Biotech (Santa Cruz, CA). A calpain activity measurement kit was from Promega (Madison, WI). The U6 promoter-driven siRNA vector (pRNAT-U6.1/Neo for EGFR, SGLT1, and their scrambled controls) was constructed by Genscript Corp. (Piscataway, NJ). The target sequence for EGFR siRNA is CGCAAAGTGTGTAACGGAATA. The negative control siRNA sequence is GAACAAT-GTTGACCAGGTGA.
Cell Culture and Treatment
PC-3MM2 or DU145 cells were incubated in a high glucose (25 mM) containing MEM supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, L-glutamine in 5% CO 2 -95% air at 378C. When cells were grown to about 70% confluence, cells were then either transfected with vectors expressing either control or EGFR siRNA using a transfection reagent, GeneJuice (EMD Chemicals, Gibbstown, NJ). At 48 hr after transfection, cell culture medium was replaced with high glucose medium containing 2 mg/ ml G418 for selection of stable clones. After 3 weeks of selection, siRNA-expressing stable clones were pooled and the expression level of EGFR in control and EGFR siRNA knock down cells were measured using Western blotting analysis. To test the sensitivity of cells to adriamycin, triplicate samples of control and EGFR siRNA treated cells were seeded in six-well culture plates and cultured in high glucose MEM for 24 hr. Then the high glucose medium was replaced with medium containing 5 mM glucose, and cultured for 6 hr before drug treatment. There were five experimental groups for control cells: vehicle, AG1478 (500 nM), adriamycin (100 ng/ml), adriamycin/AG1478 and adriamycin/glucose (25 mM); there were six groups for EGFR siRNA treated cells: vehicle, AG1478, adriamycin, adriamycin/AG1478 and adriamycin/glucose (25 mM). At 24 hr after treatment, cells were harvested, fixed, and stained with propedium iodine for flow cytometry analysis.
Live Cell Imaging of Autophagy and the Activities of Caspases 3 and 7
A live cell monitoring system, Biostation (Nikon, NY), was used to produce continuous images of live
The Prostate The Prostate cells. To facilitate monitoring morphological changes and activation of caspases along with the process of autophagy, we transfected a GFP fused autophagic marker gene, microtubule-associated protein 1 light chain 3 (LC3) [26] into the control and EGFR siRNA cells. The GFP-LC3 positive cells were sorted out using a cell-sorter (BD FACSVantage SE system; BD Biosciences, Palo Alto, CA) that used green fluorescence as a selector. After cell sorting, GFP-LC3 positive cells were cultured in 35 mm cell culture dishes containing high glucose MEM. When cells completely attached, red fluorescent conjugated substrate of caspases 3/7, Image-iTLive (Invitrogen) was added into the culture medium at a final concentration of 30x dilution. After 10 min incubation, cells were washed with MEM containing 5 mM glucose and cultured in 5 mM glucose medium in the Biostation culture chamber and imaged at 5 min intervals with triple light sources for normal phase contrast, green fluorescent images (for GFP-LC3) and red fluorescent images (for monitoring the activities of caspases 3 and 7).
Western Blotting Analysis
Western blotting was used to determine the effects of EGFR siRNA on the expression level of EGFR, the level of activated EGFR (phosphorylated EGFR, pEGFR). In brief, cells were incubated for 10 min at 08C in a lysis buffer (50 mM HEPES, pH 7.4; 150 mM NaCl; 1.0% Triton X-100; 1.5 mM MgCl 2 ; 1 mM EDTA; and 1 mM phenylmethlysulfonyl fluoride). Equal amounts of proteins pooled from triplicate samples separated by 7% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were transblotted to nitrocellulose, blocked with 5% nonfat dry milk for 2 hr at room temperature, and then incubated overnight with primary antibodies (rabbit anti-EGFR, rabbit antipEGFR, and rabbit anti-actin) (all at a 1:1,000 dilution). The primary antibody-bound membranes were washed for 10 min with a washing buffer (PBS solution containing 0.1% NP40) before incubation with corresponding secondary antibodies conjugated with horseradish peroxidase (all at a 1:3,000 dilution). After a 30-min washing, immunoreactive signals were visualized by enhanced chemiluminescence.
Measurement of Calpain Activity
Triplicate control and EGFR siRNA cells were cultured in high glucose MEM in a 96-well culture plate. When cells were grown to about 80% confluence, culture medium was replaced with MEM containing 5 mM glucose. At 24 hr after culturing in 5 mM glucose medium, cells were washed with calcium free PBS before calpain measurement. A kit for measurement of calpain activity was purchased from Promega.
Calpain activity was measured according to protocols provided by the manufacturer.
Statistic Analysis
Student t-test was used to assess the difference of control and treated groups. P < 0.05 was defined as statistically significant.
RESULTS Characterization of Autophagic
Cell Death Using Live Imaging
Previously, we found that knocking down EGFR in cancer cells resulted in autophagy, which is characterized by the appearance of autophagosomes [18] . To test the impact of loss of EGFR-induced autophagy on the sensitivity of cancer cells to adriamycin, we first had to establish a window in time when autophagy is taking place. To this end, we performed a live imaging characterization of the autophagy induced by knocking down EGFR. Since EGFR knocked down cells do not undergo autophagy when cultured in medium containing high level of glucose (25 mM) [18] , for the purpose of live imaging autophagy, we were able to transfect green fluorescent protein conjugated microtubule-associated protein 1 light chain 3 (GFP-LC3) [26] into EGFR knocked down cells cultured in high glucose medium. Formation of aggregates of GFP-LC3 was used as an indicator of autophagy. Positive cells were sorted out using GFP as an indicator. To measure apoptosis in parallel, the GFP-LC3 labeled EGFR siRNA and control siRNA cells were then incubated with a red fluorescent indicator of caspases 3/7. Continuous live imaging of cell morphology, motion of GFP-LC3 and activity of caspase 3/7 was carried out by Biostation live imaging system concurrently. As shown in Figure 1A , measured The Prostate by Western blotting, the pool of cells transfected with EGFR siRNA has a significantly lower EGFR level than the pool of cells transfected with control siRNA. The formation of GFP-LC3 aggregates occurred between 8 and 48 hr after cells were cultured in medium containing 5.5 mM glucose (Fig. 1B) . The morphological changes during autophagic cell death were monitored in comparison with adriamycin induced apoptotic cell death. As shown in Figure 1C , EGFR knockdown of induced cell death characterized by two major morphological changes: (1) cell body shrinkage and (2) lack of detachment from the culture dish. The adriamycininduced cell death presented typical features of apoptotic cell death: detachment, cell body shrinkage, and membrane blebbing (Fig. 1D) .
Since calpain is involved in connecting autophagy with apoptosis [27] and our goal was to test whether loss of EGFR-induced autophagy could sensitize hormone refractory prostate cancer cells to the apoptotic toxicity of adriamycin, we measured the activity of calpain in cells carrying EGFR siRNA and in control cells cultured in medium containing 5.5 mM glucose for 24 hr. As shown in Figure 2 , the calpain activity of EGFR siRNA-treated cells was significantly higher than that of the control cells, indicating that knocking down EGFR predisposed cells to apoptosis. Fig. 3 . Liveimaging of activation of caspases 3/ 7 of PC3-MM2 cells treated with adriamycin. A: Control-siRNA cells werepre-incubated with Image-iTLive Red fluorescent substrates of caspases 3/ 7 for 10 min, then treated with adriamycin (100 ng/ml).Time-lapse images were taken. Activated caspases 3/ 7 appeared at about 8 hr after adriamycin treatment (arrows) and lasted till about 26 hr when the majority of cells were apoptotic.B: EGFR-siRNA cells were pre-incubated with Image-iTLive Red fluorescent substrates of caspases 3/ 7 for10 min, then treated with adriamycin (100 ng/ml). Time-lapse images were taken. Activated caspases 3/ 7 appeared at about 1 hr after adriamycin treatment (arrows) and lasted till about19 hr when the majority of cells were apoptotic (bar ¼ 50 mm).
The Prostate Knocking Down EGFR, But Not Inhibiting itsTyrosine Kinase Activity, Sensitized Prostate Cancer Cells to Adriamycin-Induced,Glucose Sensitive Autophagy Knowing the window of autophagy induced by knockdown of EGFR of PC3-MM2 is between 8 and 48 hr after culturing in medium containing 5.5 mM glucose, we then tested whether the effect of knocking down EGFR on the sensitivity of hormone refractory prostate cancer cells to a common chemotherapeutic drug, adriamycin. Using dual-color live imaging, red fluorescence for caspases 3/7 and green fluorescence for GFP-LC3, the processes of autophagy and apoptosis of live cells were monitored concurrently. As shown in Figure 3A , AG1478 efficiently inhibited the phosphorylation of EGFR of cells treated with AG1478 alone or cells treated with AG1478 combined with adriamycin. When the activity of caspases 3/7 were imaged, it was found that adriamycin caused activation of caspases 3/7 in cells with control siRNA at 8 hr; while EGFR siRNA cells were sensitive to adriamycin with caspases 3/7 being activated at 1 hr after treatment (Fig. 3B) . The treatment induced cell death was quantified using flow cytometry. As shown in Figure 4A , AG1478 showed efficient inhibitory effect on the phosphorylation of EGFR, but had no effect on the cytotoxicity of adriamycin (Fig. 4B) ; on the other hand, knocking down EGFR significantly enhanced the cytotoxicity of adriamycin. Since increases in extracellular glucose level can inhibit loss of EGFR-induced autophagy, we tested whether it could also inhibit the loss of EGFR-induced sensitization of cancer cells to adriamycin. Culturing cells in medium containing 25 mM glucose completely reversed the loss of EGFR-induced sensitization of PC3-MM2 cells to adriamycin (Fig. 4B) .
To test whether loss of EGFR can also sensitize another type of commonly used hormone refractory prostate cancer cell to adriamycin, we knocked down EGFR of Du145 cells with siRNA. As shown in Figure 5A , the content of EGFR of Du145 cells was reduced by more than 70% by siRNA. Culturing cells in 5.5 mM glucose containing medium resulted in cleavage of LC3 of EGFR-siRNA treated cells at 36 hr, however, which could not be completely blocked by treating cells with 25 mM glucose (Fig. 5B) . When these cells were treated with adriamycin in the presence/absence of AG1478, it was found that, similar to PC3-MM2 cells, loss of EGFR but not inhibiting its kinase activity significantly sensitized Du145 cells to adriamycin (Fig. 5C ). The loss of EGFR induced sensitization to adriamycin; however, this sensitivity could not be inhibited by 25 mM glucose treatment (Fig. 5C ).
DISCUSSION
Although EGFR is over-expressed in prostate cancers, especially cancers of advanced stages [8, 9] , disappointingly, no beneficial effect has been observed when targeting the kinase activity of EGFR is combined with standard chemotherapies [10, [28] [29] [30] [31] . Overexpression of EGFR contributes significantly to the progression of prostate cancer, particularly to the development of hormone-refractory phase [32] [33] [34] . The clinical failure of targeting the kinase of EGFR for prostate cancer treatment warrants a re-evaluation on the value of EGFR as a therapeutic target for this type of cancer.
We have recently reported that EGFR has a kinase independent pro-survival function, preventing cancer cells from undergoing autophagy by maintaining Fig. 4 . Comparisons of cytotoxicity of adriamycin on PC3 -MM2 cells treated with AG1478 and EGFR-siRNA. A: Western Blotting analysis of phosphorylated EGFR (pEGFR) of control (Con), AG1478 treated (AG) and AG1478 þ adriamycin (AG/ADR).Total EGFR (EGFR) and actin were used as loading controls. B: Flow cytometry measurement of sub-G1 cells. Samples were harvested at 24 hr after treatment (samples in triplicates were used in each group) (values ¼ mean ± SD, * statistic difference between linked groups, P < 0.05).
The Prostate intracellular glucose [18] . The autophagic phenotype caused by knocking down EGFR was further characterized in this study. Evidence supporting a crucial kinase independent function of EGFR exists. EGFR knockout animals die soon after birth [16] , but animals with severely compromised EGFR kinase activity are completely viable and display only epithelial defects [17] . In one study, both the wild-type and kinase-dead EGFR showed a pro-survival role in EGFR negative 32D hematopoietic cells [11] .
Although EGFR contributes to cell survival, data supporting a role for EGFR tyrosine kinase activity in this cellular function remains inconclusive. Two types of cell survival exist: basal-survival and survival-under-stress. Basal-survival refers to cells maintaining a viable status under normal physiological conditions while survival-under-stress refers to the ability of cells to remain viable under harmful conditions, such as exposure to cytotoxic compounds, irradiation, hypoxia, etc. The molecular mechanisms underlying basic-survival and survival-under-stress may not necessarily coincide. Treating cells with EGFR tyrosine kinase inhibitors alone normally leads to cell growth arrest, not cell death [35, 36] , but co-treatment of cells with EGFR kinase inhibitors and cytotoxic stimuli, such as chemotherapeutic drugs, apoptotic inducers, and irradiation, results in enhanced cell death [5, 37, 38] . Overexpression of wild-type EGFR promotes cell survival in conditions of cytotoxic stress [39, 40] . What is not easy to understand is why pre-treatment with EGFR tyrosine kinase inhibitors protects cells from chemotherapeutic drugs [41] [42] [43] . These conflicting data could be due to the timing of EGFR kinase inhibition. The synergistic cytotoxic effect produced by co-treatment of cells with EGFR tyrosine kinase inhibitors and cytotoxic drugs might be explained by the instant suppression of cell survival pathways, such as PI3-Akt and MAPK pathways, by tyrosine kinase inhibition [40] . On the other hand, pre-treatment of cells with tyrosine kinase inhibitors results in cell growth arrest at the G1 phase of cell cycle, and arrest at G1 promotes resistance to certain chemotherapeutic drugs [44, 45] .
The autophagic response caused by knocking down EGFR but not by inhibiting its kinase [12, 13, 18] suggests that EGFR has a kinase independent probasal-survival function and opens a new window of targeting EGFR for prostate cancer therapy. Autophagy can sensitize cells to apoptosis via activation of calpain [27] , a calcium-dependent non-lysosomal cysteine protease. As predicated, treatment of EGFR knock-down cells with adriamycin at the window when autophagy is ongoing (within 45 hr after culturing in medium containing 5.5 mM glucose) caused significantly more apoptotic cell death than co-treating cells with EGFR kinase inhibitor, AG1478, and adriamycin. The early death in EGFR knock-down cells correlated with a much earlier activation of caspases 3/7. Previously we found that knockdown of EGFR induced autophagy was extracellular glucose dependent [18] . This also applies to the EGFR knockdown induced sensitization of PC3-MM2 cells to adriamycin, which was completely reversed by 25 mM glucose. Knocking down EGFR in another hormone refractory prostate cancer cell line, Du145, also resulted in sensitization to adriamycin. However, 25 mM glucose failed to rescue the EGFR knockdown induced sensitization of Du145 cells to adriamycin, which suggests that loss of EGFR induced autophagic phenotypes of PC3-MM2 and Du145 are mediated by different mechanisms. Prostate cancer cells differ in their metabolisms [46] The Prostate and expression of metabolic related genes such as p53 [47, 48] . While the mechanism that prevents adriamycin treated Du145-EGFR knockdown cells from being rescued by glucose warrants further investigation, nevertheless, loss of EGFR lead to sensitization of both types of hormone refractory prostate cancer cells to adriamycin. It is concluded that decreasing the amount of EGFR protein might be an effective approach for EGFR targeted therapy for prostate cancer.
